Daniel J. L. Coleman

Daniel J. L. Coleman

Auto-generated profile, based on publicly available information

Daniel J. L. Coleman

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SASalam A. Assi
Salam A. Assi
MIMaria Rosaria Imperato
Maria Rosaria Imperato
DCDaniel J. L. Coleman
Daniel J. L. Coleman
APAnna Pickin
Anna Pickin
SPSandeep Potluri
Sandeep Potluri
CBConstanze Bonifer
Constanze Bonifer

1 October 2018 in Cancer Cell
Verified
Journal Article
Open access
NMNatalia Martinez-Soria
Natalia Martinez-Soria
LMLynsey McKenzie
Lynsey McKenzie
JDJulia Draper
Julia Draper
APAnetta Ptasinska
Anetta Ptasinska
HIHasan Issa
Hasan Issa
OHOlaf Heidenreich
Olaf Heidenreich
Oncogenic transcription factors such as the leukemic fusion protein RUNX1/ETO, which drives t(8;21) acute myeloid leukemia (AML), constitute cancer-specific but highly challenging therapeutic targets. We used epigenomic profiling data for an RNAi screen to interrogate the transcriptional network maintaining t(8;21) AML. This strategy identified Cyclin D2 (CCND2) as a crucial transmitter of RUNX1/ETO-driven leukemic propagation. RUNX1/ETO cooperates with AP-1 to drive CCND2 expression. Knockdown or pharmacological inhibition of CCND2 by an approved drug significantly impairs leukemic expansion of patient-derived AML cells and engraftment in immunodeficient murine hosts. Our data demonstrate that RUNX1/ETO maintains leukemia by promoting cell cycle progression and identifies G1 CCND-CDK complexes as promising therapeutic targets for treatment of RUNX1/ETO-driven AML.

22 March 2016 in Separation Science and Technology
Verified
Journal Article
Open access
Elif Caliskan SalihiElif Caliskan Salihi
Elif Caliskan Salihi
JWJiabin Wang
Jiabin Wang
DCDaniel J. L. Coleman
Daniel J. L. Coleman
LSLidija Siller
Lidija Siller
In this paper, a one-pot and easy-to-handle method at room temperature without additional chemicals for the modification of graphene oxide (GO) with surfactant is found. Removal of nickel (II) ions from aqueous solutions by GO and surfactant (sodium dodecyl sulphate) modified graphene oxide (SDS-GO) was studied spectrophotometrically at room temperature as a function of time, initial concentration and pH. Adsorption capacity of the adsorbent was increased dramatically (from 20.19 to 55.16 mg/g found by Langmuir model) due to the functionalization of the surface by SDS. The driving force of the adsorption of Ni(II) ions is electrostatic attraction and Ni(II) ions adsorbed on the GO surface chemically besides ion exchange.

25 May 2016 in Leukemia
Verified
Journal Article
Open access
DPD Pal
D Pal
HBH J Blair
H J Blair
AEA Elder
A Elder
KDK Dormon
K Dormon
KRK J Rennie
K J Rennie
JVJ Vormoor
J Vormoor
Lack of suitable in vitro culture conditions for primary acute lymphoblastic leukaemia (ALL) cells severely impairs their experimental accessibility and the testing of new drugs on cell material reflecting clonal heterogeneity in patients. We show that Nestin-positive human mesenchymal stem cells (MSC) support expansion of a range of biologically and clinically distinct patient-derived ALL samples. Adherent ALL cells showed an increased accumulation in the S-phase of the cell cycle and diminished apoptosis when compared to cells in the suspension fraction. Moreover, surface expression of adhesion molecules CD34, CDH2 and CD10 increased several folds. About 20% of the ALL cells were in G0 phase of the cell cycle suggesting that MSCs may support quiescent ALL cells. Cellular barcoding demonstrated long-term preservation of clonal abundance. Expansion of ALL cells for more than 3 months compromised neither feeder dependence nor cancer initiating ability as judged by their engraftment potential in immunocompromised mice. Finally, we demonstrate the suitability of this co-culture approach for the investigation of drug combinations with luciferase-expressing primograft ALL cells. Taken together, we have developed a preclinical platform with patient-derived material that will facilitate the development of clinically effective combination therapies for ALL.

14 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSophie G. Kellaway
Sophie G. Kellaway
SPSandeep Potluri
Sandeep Potluri
PKPeter Keane
Peter Keane
HBHelen J. Blair
Helen J. Blair
LALuke Ames
Luke Ames
CBConstanze Bonifer
Constanze Bonifer
Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly proliferating blast cell population with fatal consequences for the patient if not treated. The most common treatment option is still chemotherapy which targets such cells. However, patients harbour a population of quiescent leukemic stem cells (LSCs) which can emerge from quiescence to trigger relapse after therapy. The processes that allow such cells to re-grow remain unknown. Here, we examine the well characterised t(8;21) AML sub-type as a model to address this question. Using four primary AML samples and a novel t(8;21) patient-derived xenograft model, we show that t(8;21) LSCs aberrantly activate the VEGF and IL-5 signalling pathways. Both pathways operate within a regulatory circuit consisting of the driver oncoprotein RUNX1::ETO and an AP-1/GATA2 axis allowing LSCs to re-enter the cell cycle while preserving self-renewal capacity.

1 December 2013 in Journal of Controlled Release
Verified
Journal Article
Open access
MPMarta Omedes Pujol
Marta Omedes Pujol
DCDaniel J.L. Coleman
Daniel J.L. Coleman
CAChristopher D. Allen
Christopher D. Allen
OHOlaf Heidenreich
Olaf Heidenreich
DFDavid A. Fulton
David A. Fulton
Short interfering ribonucleic acids (siRNAs) offer a highly specific and selective form of therapy for diseases with a genetic component; however the poor pharmacokinetic properties of the molecule have impeded its development into a therapeutic for use in vivo. Several different approaches have been taken to develop a successful siRNA delivery system but these systems lack the flexibility for easy optimisation. Here, we propose a polymeric nanoparticle (PNP) system consisting of two amphiphilic diblock copolymers which allow for the rapid determination of structure-activity relationships involving gene knockdown and toxicity. The diblock copolymers self-assemble into monodisperse micelles of defined hydrodynamic diameters ranging from 30 to 100 nm dependent on the copolymer ratio. A luciferase-based high throughput assay varying PNP composition, concentration and siRNA concentration allowed the rapid identification of efficient PNP formulations for adherent and suspension cell lines. Optimised PNPs efficiently knocked down a fusion oncogene in hard to transfect human leukaemic cells raising the possibility of targeting malignant cells in a cancer-specific fashion. This approach allows the optimum PNP formulation to be identified for different cell types and conditions.